Search

Search Results

• Level and Serum Metabolism of Homocysteine in Chronic Myeloid Leukemia Patients: A Literature Review

  K.S. Samarina, Yuliana Yurevna Assesorova, I.V. Berger

  162-171

  01.04.2026

• Phase 3 Clinical Trial of 300 mg Vamotinib Directly Compared with High-Dose Imatinib in Chronic Myeloid Leukemia Patients in Chronic Phase with Failure of Standard-Dose Imatinib: Interim Analysis

  A.G. Turkina, O. Yu. Vinogradova, E.G. Lomaia, B.A. Bakirov, N.M. Kalimulina, T.V. Shelekhova, I.L. Davydkin, T.I. Pospelova, O.A. Shukhov, E.Yu. Chelysheva, V.A. Shuvaev, S. Lavana, V. Khushoo, S. Apte, T.K. Dolai, R.K. Sahoo, Germes Grigorevich Chilov

  1-13

  01.01.2026

• The Role of Somatic Mutations in Various Genes and the Issue of Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients: A Literature Review

  Elena Andreevna Kuzmina, E.Yu. Chelysheva, B.V. Biderman, A.G. Turkina

  10-20

  01.01.2025

• Treatment Outcomes with Asciminib, the First Allosteric BCR::ABL1 Tyrosine Kinase Inhibitor, in Chronic Myeloid Leukemia Patients with Multiple Resistance to Prior Therapy

  A.G. Turkina, Elena Andreevna Kuzmina

  311-320

  09.06.2023

• Asciminib in Chronic Myeloid Leukemia Patients Without Therapeutic Alternatives: Results of the MAP (Managed Access Program, NCT04360005) Trial in Russia

  A.G. Turkina, Elena Andreevna Kuzmina, E.G. Lomaia, E.V. Morozova, E.Yu. Chelysheva, O.A. Shukhov, A.N. Petrova, T.V. Chitanava, Yu.Yu. Vlasova, I.S. Nemchenko, A.V. Bykova, E.I. Sbityakova, M.A. Gurianova, N.N. Tsyba, A.V. Kokhno, E.N. Parovichnikova

  54-68

  01.01.2023

• Expression of the BCR-ABL1 Gene in Patients with Chronic Myeloproliferative Diseases with Signs of Progression

  L.A. Kesaeva, E.N. Misyurina, D.S. Mar’in, E.I. Zhelnova, A.Yu. Bulanov, A.E. Misyurina, A.A. Krutov, I.N. Soldatova, S.S. Zborovskii, V.A. Misyurin, V.V. Tikhonova, Yu.P. Finashutina, O.N. Solopova, N.A. Lyzhko, A.E. Bespalova, N.N. Kasatkina, A.V. Ponomarev, M.A. Lysenko, Andrei Vital’evich Misyurin

  354-359

  01.10.2018